18 Jan Luminary Therapeutics
Jeff Liter, President and CEO
April 21 | 9:30am | Gaudi 2 Ballroom
Minneapolis, MN
(Private)
In-Person Presentation
Luminary Therapeutics is a preclinical gene modified cellular therapy development company. We expect to launch our first clinical trial in Q1 2022 with a novel three-receptor ligand CAR designed to overcome antigen escape. The primary focus of the company is superior cell engineered CARs and TCRs designed to create cellular therapies that abate antigen escape and T cell exhaustion. Luminary was founded by the team from B-MoGen who developed TcBuster and had a successful 5x exit in three years. We are seeking a Series A financing with either venture firms or strategic alliances that will support our first clinical trial and the development of our disruptive U-Receptor CAR that can modulate antigen specificity.
